ClinicalTrials.gg
CompletedNCT00135369Updated Apr 25, 2011

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

A Phase 3 interventional study of stavudine extended-release, lamivudine, efavirenz in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 47 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-25.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing stavudine in HIV Infections — none open to participants now, none under way, none of them phase 3. Stavudine · HIV Infections.

Enrollment
6th of 39
300 · median 100
Started
2002
with 1 other
Phase 3
13 of 46
none open now
Registered
41st of 46
by date
Lead sponsor
14 of 46
Bristol-Myers Squibb

Among the 46 studies testing stavudine in HIV Infections, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2002, is one of 13 in phase 3, and was the 41st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 46 studies testing stavudine in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About stavudine

Stavudine: first FDA approval 1994 (ZERIT), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing stavudine in HIV Infections as a file.
02

Study summary

The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a standard-of-care regimen dosed twice-daily or more frequently to a simpler once-daily (QD) regimen while maintaining virologic control, as evaluated by the proportion of subjects who continue to have plasma HIV-1 levels \<50 copies/mL after switching to a QD regimen.

03

Conditions studied

  • HIV Infections

Keywords

  • HIV-AIDS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented infection
  • 18 years of age or older and weigh at least 40 kg
  • Two plasma HIV RNA levels below the limit of quantification (one at least 90 days prior to the screening visit and one within 30 days of the patients baseline visit)
  • Currently receiving a standard-of-care HAART regimen with at least one agent being dosed twice-daily or more frequently

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding or plans to become pregnant during the study period
  • Any prior documented virologic failure to one or more HAART regimens
  • Active AIDS-defining opportunistic infection or disease
  • Proven or suspected acute hepatitis within 30 days prior to study entry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy at week 48

Secondary outcomes

  1. Safety, tolerability and efficacy at weeks (wks) 24 and 48; Effect on lipids at wks 24 and 48; Adherence, quality of life changes, treatment satisfaction and preference at wks 12, 24 and 48

07

Study locations

47 sites
  • Local Institution
    Hobson City, Alabama, United States
  • Local Institution
    Montgomery, Alabama, United States
  • Local Institution
    Phoenix, Arizona, United States
  • Local Institution
    Little Rock, Arkansas, United States
  • Local Institution
    Los Angeles, California, United States
  • Local Institution
    Sacramento, California, United States
  • Local Institution
    San Mateo, California, United States
  • Local Institution
    Torrance, California, United States
  • Local Institution
    Denver, Colorado, United States
  • Local Institution
    Norwalk, Connecticut, United States
  • Local Institution
    Stratford, Connecticut, United States
  • Local Institution
    Washington, District of Columbia, United States
  • Local Institution
    Ft. Lauderdale, Florida, United States
  • Local Institution
    Miami Beach, Florida, United States
  • Local Institution
    Miami, Florida, United States
  • Local Institution
    Pensacola, Florida, United States
  • Local Institution
    Tampa, Florida, United States
  • Local Institution
    Decatur, Georgia, United States
  • Local Institution
    Chicago, Illinois, United States
  • Local Institution
    Indianapolis, Indiana, United States
  • Local Institution
    New Orleans, Louisiana, United States
  • Local Institution
    Baltimore, Maryland, United States
  • Local Institution
    Boston, Massachusetts, United States
  • Local Institution
    Berkley, Michigan, United States
  • Local Institution
    Detroit, Michigan, United States
  • Local Institution
    St. Louis, Missouri, United States
  • Local Institution
    Las Vegas, Nevada, United States
  • Local Institution
    Hackensack, New Jersey, United States
  • Local Institution
    Jersey City, New Jersey, United States
  • Local Institution
    Neptune, New Jersey, United States
  • Local Institution
    Somers Point, New Jersey, United States
  • Local Institution
    Bronx, New York, United States
  • Local Institution
    Manhasset, New York, United States
  • Local Institution
    New York, New York, United States
  • Local Institution
    Charlotte, North Carolina, United States
  • Local Institution
    Huntersville, North Carolina, United States
  • Local Institution
    Washington, North Carolina, United States
  • Local Institution
    Winston-Salem, North Carolina, United States
  • Local Institution
    Philadelphia, Pennsylvania, United States
  • Local Institution
    Reading, Pennsylvania, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Galveston, Texas, United States
  • Local Institution
    Houston, Texas, United States
  • Local Institution
    Annandale, Virginia, United States
  • Local Institution
    Hampton, Virginia, United States
  • Local Institution
    Seattle, Washington, United States
  • Local Institution
    San Juan, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of Jul 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 26, 2005
Start
Sep 2002
Primary completionActual
Jul 2005
CompletionActual
Jul 2005
Results delay requested
Jan 28, 2010
Last update
Apr 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00135369
First posted
Aug 26, 2005
Start date
Sep 2002
Primary completion
Jul 2005
Completion
Jul 2005
Last update
Apr 25, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Stavudine · Lamivudine · Efavirenz

Start the discussion